Home > Healthcare & Medical Devices > Cell Culture Media Market
The cell culture media market was valued at around USD 5 billion in 2022 and is set to rise at a 15-20% CAGR from 2023 to 2032. A basic culture medium contains amino acids, vitamins, inorganic salts, glucose, and serum to provide hormones and growth & attachment factors. The medium typically includes an adequate supply of energy and substances that control the cell cycle.
The increasing demand for biopharmaceuticals, favourable government policies, and rising R&D investments are expected to drive market landscape over the forecast period. The new facility will develop & produce innovative cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medicinal applications. It will allow FUJIFILM Irvine Scientific to fulfill the rising market development for high-quality cell culture medium solutions.
According to the product type, the Serum-free Media (SFM) segment holds the largest market share. SFM is an essential tool that allows researchers to execute specialized applications or develop a certain cell type without utilizing a serum. The use of SFM offers increased growth and/or productivity, more consistent performance, improved control over physiological sensitivity, and reduced chances of infection in the culture through serum-borne adventitious agents. Serum-free alternatives benefit animal welfare, which is a major factor driving SFM adoption.
According to the application, biopharmaceutical production is expected to hold a large market share by 2032. The biopharmaceutical industry's drive for more repeatable and better-defined media to match increased production levels while decreasing the risks of contamination in downstream procedures is driving segment progress. Biopharmaceutical companies are focused on expanding their production capacities, further boosting market outlook.
North America dominates the cell culture media market due to the progression & improvement of cell-based assays, such as cellular expression, and pluripotent stem cell research, along with the abundance of market competitors in the region. In March 2023, Nucleus Biologics, a leading provider of custom cell culture media solutions for the cell & gene therapy industry, and Stoic Bio, a provider of sustainable technology for cell media manufacturing, signed a supply agreement with the Center for Breakthrough Medicines (CBM), a leading Contract Development & Manufacturing Organization (CDMO). Under this agreement, Nucleus Biologics will consistently supply cell culture media and other important biological solutions for CBM with stringent quality control procedures.
The prominent players in the cell culture media market are Thermo Fisher Scientific Inc., Merck KGaA, CYTIVA, Sartorius AG, FUJIFILM Irvine Scientific, Inc., Lonza Group AG, InvivoGen, STEMCELL Technologies Inc., PromoCell GmbH, and Cell Biologics, Inc.